Infliximab, azathioprine, or combination therapy for Crohn's disease
about
Epidemiology and clinical course of Crohn's disease: results from observational studiesOnset of psoriasis in patients with inflammatory bowel disease treated with anti-TNF agentsAntibody development against biologic agents used for the treatment of inflammatory bowel disease and antibody prevention with immunosuppressivesAzathioprine or 6-mercaptopurine for maintenance of remission in Crohn's diseaseAnti-IL-12/23p40 antibodies for induction of remission in Crohn's diseaseAzathioprine or 6-mercaptopurine for induction of remission in Crohn's diseaseVedolizumab for the treatment of ulcerative colitis and Crohn's diseaseOptimizing 6-mercaptopurine and azathioprine therapy in the management of inflammatory bowel diseaseOptimal delivery of follow-up care after surgery for Crohn's disease: current perspectivesInflammatory bowel disease surgery in the biologic eraPredicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel diseaseThe clinical potential of etrolizumab in ulcerative colitis: hypes and hopesClinical experience with infliximab biosimilar Remsima (CT-P13) in inflammatory bowel disease patientsImplementation of the simple endoscopic activity score in crohn's diseaseSelective biologics for ulcerative colitis and Crohn's disease - clinical utility of vedolizumabFecal calprotectin in inflammatory bowel diseaseElderly patients and inflammatory bowel diseaseHow should immunomodulators be optimized when used as combination therapy with anti-tumor necrosis factor agents in the management of inflammatory bowel disease?Current stage in inflammatory bowel disease: What is next?Crohn's disease: a clinical updatePharmacologic therapy for inflammatory bowel disease refractory to steroidsPatient considerations in the management of ulcerative colitis - role of vedolizumabReview article: dermatological complications of immunosuppressive and anti-TNF therapy in inflammatory bowel diseaseTyro3, Axl, and Mertk receptor signaling in inflammatory bowel disease and colitis-associated cancerUse of thiopurines in inflammatory bowel diseaseProfile of ustekinumab and its potential in patients with moderate-to-severe Crohn's disease.Hepatitis B and C virus reactivation in immunosuppressed patients with inflammatory bowel diseaseAdalimumab treatment in Crohn's disease: an overview of long-term efficacy and safety in light of the EXTEND trialMucosal healing and deep remission: what does it mean?Therapeutic drug monitoring in inflammatory bowel diseaseAssessing patient preferences for treatment options and process of care in inflammatory bowel disease: a critical review of quantitative dataA review of the impact of biologics on surgical complications in Crohn's diseaseOptimization of the treatment with immunosuppressants and biologics in inflammatory bowel diseaseRisk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studiesReview article: the role of anti-TNF in the management of ulcerative colitis -- past, present and futureImpact of medical therapies on inflammatory bowel disease complication rateTrial Watch: Immunomodulatory monoclonal antibodies for oncological indicationsEvaluation of inflammatory activity in Crohn's disease and ulcerative colitisUse of Thiopurines in Inflammatory Bowel Disease: A Consensus Statement by the Korean Association for the Study of Intestinal Diseases (KASID)Biologics in the management of ulcerative colitis - comparative safety and efficacy of TNF-α antagonists
P2860
Q22241217-76D66A33-DC39-4180-82A2-AD3DE89CC882Q22305935-A26CAD4E-6920-4183-9639-A71EB88832E3Q24185835-FD3157FF-ABFB-4919-AC58-3978E694E94CQ24186291-F9FAE4DA-8DA5-4ADD-AABB-614D8EBC5A27Q24188040-D6AB8CB9-B4BA-4558-9E5C-8E0330B1840CQ24197676-A8C601C3-B2CD-4397-B26F-44196CF36A7DQ24630083-31BF0CE3-CD5D-4EE1-A66B-D36E5D456826Q24631869-3D70ED6B-83E3-437B-8625-12D3C705F069Q26740356-2D60E1F6-E2A0-46BF-AFEB-9993E2534F79Q26745627-D911FC9B-1321-42EC-86F0-C067987EE47CQ26745721-73FF7F3A-DB3B-48F2-B248-933D02522620Q26745725-57A902F9-2230-443F-B78E-5D4C64BF435AQ26748630-16AFAECF-B127-4D8E-AF7B-DC20C7EC22DAQ26749323-2C5A53A0-E71F-4060-8699-C9608C202C60Q26750456-F4313073-7141-4A46-AB38-5BF34EE8117AQ26766527-1C2167D3-5470-4A47-B771-6BEB41FD4E73Q26768270-9FB2B95C-730F-4A9C-A606-6726B06A6263Q26777409-2CF5A85B-97C1-4821-AC29-34F76D23D93DQ26777429-B8015569-5293-4FE2-BA93-173BD0B8302FQ26777696-44762916-79CD-4ECE-8CB8-57A52D59315FQ26796415-BAF0FEF9-0233-4B39-A198-A54E4FC370E7Q26796432-8BE7D2A2-F17D-426A-A48B-52B02705FBB3Q26822029-B7A041AC-EE63-464E-B916-3DDFF15DA2F5Q26823237-E01A59EF-330B-45E5-889C-BDFB1A62CE2DQ26824662-05DBD834-3B49-45FB-A29B-5903F723CDB8Q26825174-C592BED7-A12C-4703-A0A8-242187E5EE44Q26827444-02C38E02-5F42-43DB-9A71-5B610D2CB67EQ26829488-16C38C5D-3AFC-4C34-8DB1-F2B8FD209EFCQ26852447-3C11F93A-A322-4BC2-AA43-D76454DC8991Q26852729-90A77097-E88B-462C-8F20-2152FFD85D2CQ26864906-03F23C8B-2B77-4C9A-953C-C7DA101A7B58Q26865009-8DB78B22-EAF1-4DF0-96EE-1E1473C19AC9Q26866940-2AD8748D-E00C-4A95-8037-563DD9E4234FQ26991673-3479A08C-A135-4476-B7D0-C9DB11A68737Q26992012-F99BA8A9-ABEB-4C0A-BDD8-2E3AE480102FQ26995479-5D128B1D-A044-4430-BE61-4927E34797A7Q26996518-3ACAAF37-2D2F-46E0-93C7-93B89E88C799Q26996550-368CFEE9-50DB-4FE6-9248-495D8985D824Q26996946-640A8C3F-6180-427B-B053-70A77D86DF15Q26999078-95B569E3-680E-478C-833D-CB43314291C3
P2860
Infliximab, azathioprine, or combination therapy for Crohn's disease
description
article
@en
im April 2010 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована у квітні 2010
@uk
name
Infliximab, azathioprine, or combination therapy for Crohn's disease
@en
Infliximab, azathioprine, or combination therapy for Crohn's disease
@nl
type
label
Infliximab, azathioprine, or combination therapy for Crohn's disease
@en
Infliximab, azathioprine, or combination therapy for Crohn's disease
@nl
prefLabel
Infliximab, azathioprine, or combination therapy for Crohn's disease
@en
Infliximab, azathioprine, or combination therapy for Crohn's disease
@nl
P2093
P50
P356
P1476
Infliximab, azathioprine, or combination therapy for Crohn's disease
@en
P2093
Asher Kornbluth
C Janneke van der Woude
Daniel Rachmilewitz
Delma L Broussard
Geert D'Haens
Gerassimos J Mantzaris
Kezhen L Tang
Robert H Diamond
Simon Lichtiger
Walter Reinisch
P304
P356
10.1056/NEJMOA0904492
P407
P577
2010-04-15T00:00:00Z